When playing the NK cell therapy card in glioblastoma, you can’t beat interleukin-21
IF 48.8
1区 医学
Q1 CELL BIOLOGY
引用次数: 0
Abstract
Glioblastoma is the most common brain cancer, with a 5-year survival rate of less than 10%. This grim prognosis highlights the urgent need for novel therapeutic approaches. In this issue of Cancer Cell, Shanley et al.1 report an innovative engineering strategy to supercharge NK cell immunity against glioblastoma.
在胶质母细胞瘤中使用 NK 细胞疗法时，白细胞介素-21 是不可或缺的。
胶质母细胞瘤是最常见的脑癌，5 年生存率不到 10%。这种严峻的预后凸显了对新型治疗方法的迫切需求。在本期《癌细胞》（Cancer Cell）杂志上，Shanley 等人1 报告了一种创新的工程策略，它能增强 NK 细胞对胶质母细胞瘤的免疫力。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助全文
约1分钟内获得全文
求助全文
来源期刊
Cancer Cell
医学-肿瘤学
CiteScore
55.20
自引率
1.20%
发文量
179
审稿时长
4-8 weeks
期刊介绍：
Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows:
Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers.
Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice.
Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers.
Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies.
Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.
文献相关原料
| 公司名称 | 产品信息 | 采购帮参考价格 |
|---|
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
